GlassScriptPhysician profile
Niranjan N Jani
NPI 1891752424
$1,358.17
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $810.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $276.43 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $267.98 | 2019-2020 | |
| Alkermes, INC. | $214.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $196.82 | 2019-2020 | |
| Lundbeck LLC | $122.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.65 | 2020 | |
| Allergan, INC. | $41.92 | 2020 | |
| Neurocrine Biosciences, INC. | $32.89 | 2020 | |
| Orexo US, INC. | $26.56 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $24.45 | 2020 | |
| Avanir Pharmaceuticals, INC. | $18.57 | 2020 | |
| Shire North American Group INC | $18.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.64 | 2020 | |
| Indivior INC. | $17.45 | 2020 | |
| Olympus America INC. | $15.68 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranjan Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.